skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies

Abstract

We report the synthesis and biological evaluation of phenylcarboxylic acid and phenylboronic acid containing HIV-1 protease inhibitors and their functional effect on enzyme inhibition and antiviral activity in MT-2 cell lines. Inhibitors bearing bis-THF ligand as P2 ligand and phenylcarboxylic acids and carboxamide as the P2' ligands, showed very potent HIV-1 protease inhibitory activity. However, carboxylic acid containing inhibitors showed very poor antiviral activity relative to carboxamide-derived inhibitors which showed good antiviral IC50 value. Boronic acid derived inhibitor with bis-THF as the P2 ligand showed very potent enzyme inhibitory activity, but it showed lower antiviral activity than darunavir in the same assay. Boronic acid containing inhibitor with a P2-Crn-THF ligand also showed potent enzyme Ki but significantly decreased antiviral activity. We have evaluated antiviral activity against a panel of highly drug-resistant HIV-1 variants. One of the inhibitors maintained good antiviral activity against HIVDRVRP20 and HIVDRVRP30 viruses. We have determined high resolution X-ray structures of two synthetic inhibitors bound to HIV-1 protease and obtained molecular insight into the ligand-binding site interactions.

Authors:
ORCiD logo [1];  [1];  [1];  [1];  [1];  [2];  [2];  [3];  [4];  [2];  [5]
  1. Purdue Univ., West Lafayette, IN (United States)
  2. Georgia State Univ., Atlanta, GA (United States)
  3. National Cancer Inst., Bethesda, MD (United States); National Center for Global Health and Medicine Research Inst., Tokyo (Japan)
  4. National Center for Global Health and Medicine Research Inst., Tokyo (Japan)
  5. Kumamoto Univ. (Japan); National Cancer Inst., Bethesda, MD (United States); National Center for Global Health and Medicine Research Inst., Tokyo (Japan)
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
USDOE Office of Science (SC), Basic Energy Sciences (BES); National Institutes of Health (NIH); Japan Agency for Medical Research and Development (AMED)
OSTI Identifier:
1577162
Grant/Contract Number:  
AI150466; AI150461; R01AI121315; JP15fk0410001; JP18fk0410001; W-31-109-ENG-38
Resource Type:
Journal Article: Accepted Manuscript
Journal Name:
ChemMedChem
Additional Journal Information:
Journal Volume: 14; Journal Issue: 21; Journal ID: ISSN 1860-7179
Publisher:
ChemPubSoc Europe
Country of Publication:
United States
Language:
ENGLISH
Subject:
60 APPLIED LIFE SCIENCES; brain penetration; drug resistance; genetic barriers; HIV-1 protease inhibitors; structure-based design

Citation Formats

Ghosh, Arun K., Xia, Zilei, Kovela, Satish, Robinson, William L., Johnson, Megan E., Kneller, Daniel W., Wang, Yuan‐Fang, Aoki, Manabu, Takamatsu, Yuki, Weber, Irene T., and Mitsuya, Hiroaki. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies. United States: N. p., 2019. Web. doi:10.1002/cmdc.201900508.
Ghosh, Arun K., Xia, Zilei, Kovela, Satish, Robinson, William L., Johnson, Megan E., Kneller, Daniel W., Wang, Yuan‐Fang, Aoki, Manabu, Takamatsu, Yuki, Weber, Irene T., & Mitsuya, Hiroaki. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies. United States. https://doi.org/10.1002/cmdc.201900508
Ghosh, Arun K., Xia, Zilei, Kovela, Satish, Robinson, William L., Johnson, Megan E., Kneller, Daniel W., Wang, Yuan‐Fang, Aoki, Manabu, Takamatsu, Yuki, Weber, Irene T., and Mitsuya, Hiroaki. 2019. "Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies". United States. https://doi.org/10.1002/cmdc.201900508. https://www.osti.gov/servlets/purl/1577162.
@article{osti_1577162,
title = {Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies},
author = {Ghosh, Arun K. and Xia, Zilei and Kovela, Satish and Robinson, William L. and Johnson, Megan E. and Kneller, Daniel W. and Wang, Yuan‐Fang and Aoki, Manabu and Takamatsu, Yuki and Weber, Irene T. and Mitsuya, Hiroaki},
abstractNote = {We report the synthesis and biological evaluation of phenylcarboxylic acid and phenylboronic acid containing HIV-1 protease inhibitors and their functional effect on enzyme inhibition and antiviral activity in MT-2 cell lines. Inhibitors bearing bis-THF ligand as P2 ligand and phenylcarboxylic acids and carboxamide as the P2' ligands, showed very potent HIV-1 protease inhibitory activity. However, carboxylic acid containing inhibitors showed very poor antiviral activity relative to carboxamide-derived inhibitors which showed good antiviral IC50 value. Boronic acid derived inhibitor with bis-THF as the P2 ligand showed very potent enzyme inhibitory activity, but it showed lower antiviral activity than darunavir in the same assay. Boronic acid containing inhibitor with a P2-Crn-THF ligand also showed potent enzyme Ki but significantly decreased antiviral activity. We have evaluated antiviral activity against a panel of highly drug-resistant HIV-1 variants. One of the inhibitors maintained good antiviral activity against HIVDRVRP20 and HIVDRVRP30 viruses. We have determined high resolution X-ray structures of two synthetic inhibitors bound to HIV-1 protease and obtained molecular insight into the ligand-binding site interactions.},
doi = {10.1002/cmdc.201900508},
url = {https://www.osti.gov/biblio/1577162}, journal = {ChemMedChem},
issn = {1860-7179},
number = 21,
volume = 14,
place = {United States},
year = {Fri Oct 04 00:00:00 EDT 2019},
month = {Fri Oct 04 00:00:00 EDT 2019}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 10 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Tagged Hypervalent Iodine Reagents:  A New Purification Concept Based on Ion Exchange through S N 2 Substitution
journal, December 2007


Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS
journal, January 2016


Refinement of Macromolecular Structures by the Maximum-Likelihood Method
journal, May 1997


Overview of the CCP 4 suite and current developments
journal, March 2011


Active human immunodeficiency virus protease is required for viral infectivity.
journal, July 1988


Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients
journal, January 2009


P-Glycoprotein Mediates Efflux Transport of Darunavir in Human Intestinal Caco-2 and ABCB1 Gene-Transfected Renal LLC-PK1 Cell Lines
journal, January 2009


Enhancing Protein Backbone Binding-A Fruitful Concept for Combating Drug-Resistant HIV
journal, January 2012


Sub-picomolar Inhibition of HIV-1 Protease with a Boronic Acid
journal, October 2018


Coot model-building tools for molecular graphics
journal, November 2004


A simple, continuous fluorometric assay for HIV protease
journal, December 1990


Features and development of Coot
journal, March 2010


Ultra-high Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114
journal, October 2006


Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance
journal, January 2008


Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants
journal, April 2017


A graphical user interface to the CCP 4 program suite
journal, June 2003


Fluorine substituent effects (on bioactivity)
journal, June 2001


Oxidation of α,β-un saturated aldehydes
journal, January 1981


Verstärkung der Bindung an das Proteinrückgrat - ein fruchtbares Konzept gegen die Arzneimittelresistenz von HIV
journal, January 2012


The Protein Data Bank
journal, January 2000


Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV
journal, December 2007


Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance
journal, August 2006


The mechanisms that control intracellular penetration of the HIV protease inhibitors
journal, February 2003


Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir
journal, August 2014


INHIBITORS OF HIV-1 PROTEASE: A Major Success of Structure-Assisted Drug Design
journal, June 1998


JLigand : a graphical tool for the CCP 4 template-restraint library
journal, March 2012


Phaser crystallographic software
journal, July 2007


PARP1 exhibits enhanced association and catalytic efficiency with γH2A.X-nucleosome
journal, December 2019


The Effect of Highly Active Antiretroviral Therapy on the Survival of HIV-Infected Children in a Resource-Deprived Setting: A Cohort Study
text, January 2011


Overview of the CCP4 suite and current developments.
text, January 2011